← SynDRA
RILUZOLE
SynDRA canonical compound SYN0001662 — structure-anchored drug synonym record
| Clinical phase | Launched |
| Approval status | Approved · Rx/OTC |
| Primary target(s) | SCN5A |
| Mechanism of action | Glutamate inhibitor |
| Indication | amyotrophic lateral sclerosis (ALS) |
| Disease area | neurology/psychiatry |
All known targets
- SCN5A
- SCN11A
- KCNN4
- SCN10A
- SCN9A
- SCN8A
- SCN7A
- SCN4A
- SCN3A
- SCN2A
- SCN1A
- TRPC5
Mechanisms of action (all sources)
- Glutamate inhibitor
- SCN1A BLOCKER
- Sodium channel alpha subunit blocker
- SCN5A BLOCKER
- SCN4A BLOCKER
- SCN7A BLOCKER
- SCN2A BLOCKER
- SCN9A BLOCKER
- SCN3A BLOCKER
- SCN11A BLOCKER
- SCN8A BLOCKER
- SCN10A BLOCKER
Drug classes
- Benzothiazole
- Anticonvulsants
- Central Nervous System Agents
- Excitatory Amino Acid Antagonists
- Neuroprotective Agents
- Neurotransmitter Agents
- Protective Agents
ATC classes
- N07X · OTHER NERVOUS SYSTEM DRUGS
Cross-references
Synonyms
- rilutek
- rilutor
- 6-Trifluoromethoxybenzothiazol-2-ylamine
- riluzole hydrochloride
- riluzole HCl
- RP54274
- RP-54274
- Riluzol
- Tiglutik
- BHV-0223
- NSC-753433
- NSC-759823
- Exservan
- Rilutek
- Riluzole zentiva
- Teglutik
- Tiglutik kit
- Riluzolum
- Riluzole HCl
- ALBB-006046
- BF-37
- PK-26124
- R-116
- Rilutek (TN)
- Riluzol [INN-Spanish]
- Riluzole [USAN:INN]
- Riluzolum [INN-Latin]
- ZERO/001785
- Amino-2 trifluoromethoxy-6 benzothiazole
- Amino-2 trifluoromethoxy-6 benzothiazole [French]
- Riluzole (JAN/USAN/INN)
- PK-26124, RP-54274, Rilutek, Riluzole
- 2-Amino-6-(trifluoromethoxy)-benzothiazole
- 2-Amino-6-(trifluoromethoxy)benzothiazole
- 2-Amino-6-trifluoro-methoxybenzothiazole
- 2-amino-6-(trifluoromethoxy)-1,3-benzothiazole
- 2-amino-6-(trifluoromethoxy)benzo[d]thiazole
- 2-amino-6-(trifluoromethoxyl)benzothiazole
Reported adverse events
- Interstitial lung disease
- Nausea
- Pancreatitis
- Asthenia
- Neutropenia
- Tachycardia
- Abdominal pain
- Arthralgia
- Dizziness
- Dry mouth
- Eczema
- Flatulence
Look up RILUZOLE in the interactive SynDRA portal →